Literature DB >> 35154666

Long non-coding RNA expression profiling in the lungs of pulmonary arterial hypertension rats with acute inflammation.

Yue Yang1, Yanan Cao1, Gang Qin1, Lu Wang1, Qian Li1, Sisi Dai1, Lizhe Guo1, Qulian Guo1, Yong Gang Peng2, Bin Duan1, E Wang1.   

Abstract

BACKGROUND: We performed RNA-sequencing to investigate the changes and expression profiles in long non-coding RNAs (lncRNAs) and their potential functional roles in the lungs of pulmonary arterial hypertension rats responding to acute inflammation.
METHODS: To establish a pulmonary arterial hypertension rat model, monocrotaline was injected intraperitoneally and lipopolysaccharide was given to induce acute inflammation. Selected lncRNAs were validated by quantitative real-time polymerase chain reaction (qRT-PCR). Bioinformatics analyses were carried out to predict the potential biological roles of key lncRNAs.
RESULTS: Twenty-eight lncRNAs and seven mRNAs with elevated expression and 202 lncRNAs and 36 mRNAs with decreased expression were found in the lung tissues of lipopolysaccharide-treated pulmonary arterial hypertension rats compared with control group. The qRT-PCR validation results were consistent with the bioinformatics analysis. Gene ontology analyses showed that the mRNAs and lncRNAs were differentially expressed in different pathways regarding biological process, cellular components, and molecular function. The functions of differentially expressed messenger RNAs (DEmRNAs) and DElncRNAs were indicated by Kyoto Encyclopedia of Genes and Genomes enrichment.
CONCLUSION: The DEmRNAs co-expressed with DElncRNAs were obviously enriched in inflammation. DElncRNAs and DEmRNAs in the lungs of pulmonary arterial hypertension rats changed with acute inflammation may provide new insights into the pathogenesis of pulmonary arterial hypertension.
© The Author(s) 2019.

Entities:  

Keywords:  inflammation; long non-coding RNAs; lung; messenger RNA; pulmonary arterial hypertension

Year:  2019        PMID: 35154666      PMCID: PMC8826282          DOI: 10.1177/2045894019879393

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


Background

Pulmonary arterial hypertension (PAH) is a progressive pulmonary vasculature pathological alteration that is characterized by an extreme increase in pulmonary vascular resistance, pulmonary arterial pressure, and possible right ventricular hypertrophy. Research has shown that histological lung tissue from a PAH model displayed critical vascular remodeling. Inflammation plays a critical role in the dysfunction of pulmonary arterial endothelial cells, but its specific mechanism remains inconclusive. It has been observed that when severe PAH becomes acutely inflamed, cardiac function deteriorates rapidly and even leads to death. As inflammation evidently aggravates the insult of PAH, the underlying mechanisms must be investigated. Long non-coding RNAs (lncRNAs) are defined as non-coding transcripts with a length greater than 200 nucleotides. Substantial evidence indicates that lncRNAs interact with DNA, RNA, and proteins and play key roles in many important biological processes, such as transcription regulation, post-transcription regulation, and epigenetic regulation.[4,5] Studies show the rs619586A  >  G single nucleotide polymorphism is correlated with risk of PAH. People with G variant genotypes have a lower risk of PAH compared to the rs619586AA genotype. Differential expressions of lncRNAs were observed in chronic thromboembolic pulmonary hypertension tissues and in the hypoxic PAH rat model.[7,8] What is less well known, however, is how lncRNAs change and what their potential function is in lung tissues of lipopolysaccharide (LPS)-treated PAH rats. In our study, lncRNAs and mRNA expression profiling of PAH rats in circumstances of acute inflammation were obtained through high-throughput sequencing. DElncRNAs and DEmRNAs in lungs were identified, and we also constructed an lncRNA/mRNA co-expression network. This is the first comprehensive lncRNA profile in lungs of LPS-treated PAH rats.

Methods

Animal experiments

All procedures involving animals were authorized by the Ethics Committee for Animal Research of Xiangya Hospital of Central South University (approval no. 201303311). Twenty male Sprague-Dawley rats weighted 250–300 g were purchased from the Laboratory Animal Center of Central South University (Changsha, China). To induce PAH, 1% monocrotaline (60 mg/kg, Sigma-Aldrich, St. Louis, MO, USA) was intraperitoneally injected to all rats. Rats had free access to food and water and were given a 12-h light/dark cycle in a temperature-controlled room. After 28 days, pulmonary arterial pressure was measured by echocardiography using the method of tracing the tricuspid regurgitation spectrum. If the pulmonary arterial pressure was ≥ 60 mmHg, the rats were included in the next experiment. Then, the rats were divided into two groups randomly: PAH group and PAH + LPS group. LPS (1 mg/kg) (Serotype O55:B5, Sigma-Aldrich) was intraperitoneally injected to rats in the PAH + LPS group. Two hours later, the rats were sacrificed via exsanguination under ketamine anesthesia, and lung tissues were harvested for RNA isolation.

High-throughput sequencing

Total RNA of the lung tissues from three PAH rats and three PAH rats treated with LPS were extracted using TRIZOL reagent (Invitrogen, Grand Island, NY, USA). The high-throughput sequencing work was carried out by Genergy Biotechnology (Shanghai, China). First, the RNA quality and quantity were measured by Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA). Then, 1 µg of total RNA was amplified and transcribed into ds cDNA and constructed RNA library by Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies, Carlsbad, CA, USA) and Qubit (Invitrogen). After clustering generation with cBot (Illumina, San Diego, California, USA), the arrays were scanned by the Hiseq2500 SBS (Illumina), and the raw data were subsequently processed. DElncRNAs and DEmRNAs were filtered by fold-change.

Quantitative real-time PCR

The results of high-throughput sequencing analysis were verified by quantitative real-time polymerase chain reaction (qRT-PCR). Total RNA was extracted by using TRIZOL reagent (Invitrogen) and then cDNA was synthesized by a PrimeScript™ RT regent Kit (Takara Bio Inc., Otsu, Japan). The online primer design website, primer3 (http://primer3.ut.ee/) was used to design the specific promoter primers. The following primers were used: TCONS_00321934, forward, CACGGCAAGACCAAGACAGA, reverse, TTCTCCCACGGCATTTCTCG; TCONS_00196921, forward, AAGGAAGCCCATAACGGTCAG, reverse, TCTCTGTCTCTGTGTCTCTGGT; TCONS_00107023, forward, CAGTGGCGGTGGTGATAACA, reverse, GGTTGGAGGCTGGTGAGTTC; TCONS_00243128, forward, GGCATCTGTCTGTAGGTGGTC, reverse, TTTGCTCTCCTGGGCTTGTTT; Cxcl-6, forward, CGGTCCTGCTCGTCATTCAC, reverse, CGTAGCTCCGTTGCAACCAT; Il-6, forward, CCAGTTGCCTTCTTGGGACTG, reverse, TTGTGGGTGGTATCCTCTGTGA; Lbh, forward, GAACCCACAGAAGGGGAGGT, reverse, TGTCCTGCTCATCCTCCTGG; Rtkn2, forward, CCGCTTTGATCTCAGCATTGA, reverse, GGATTCCTCCTCCCGACCAA; GAPDH, forward, TGATTCTACCCACGGCAAGTT, reverse, TGATGGGTTTCCCATTGATGA. qRT-PCR was performed to detect lncRNA and mRNA expression in lungs with ABI Prism 7900 Sequence Detection System (Applied Biosystems, Foster City, CA). Conditions for amplification were at 94℃ for 1 min and 40 cycles of 95℃ for 10 s, 60℃ for 30 s and 72℃ for 30 s. Each reaction was done in triplicate. Transcript levels of each lncRNA normalized to GAPDH were calculated using the 2−ΔΔCT method.

Functional group analysis

The functions of DE genes were detected by Gene ontology (GO) analysis. GO analysis can classify genes into hierarchical categories along biological processes, molecular functions, and cellular component and reveal gene regulatory networks. Kyoto Encyclopedia of Genes and Genomes database (KEGG) was used to analyze pathway. Two-sided Fisher’s exact test was used to analyze data, and false discovery rate was calculated and P value was corrected. P < 0.05 was considered statistically significant.

Co-expression network

To confirm lncRNAs involved in the pathogenesis of acute right ventricular failure in LPS-treated PAH rats, we selected DEmRNAs detected in this study to build a co-expression network. A Pearson correlation coefficient (PCC) was figured between the top 10 upregulated/downregulated DElncRNAs and detected mRNAs. A PCC ≥ 0.99 was considered as a significant correlation pair.

Statistical analysis

All data were presented as mean ± standard deviation. Differences between groups were determined by Student’s t-test (P < 0.05 was considered statistically significant). All results were processed using GraphPad Prism 6 Software (GraphPad, La Jolla, CA, USA).

Results

RNA sequencing of lung tissues from LPS-treated PAH rats

Lung tissues of PAH rats with or without LPS treatment were applied for RNA sequencing. After trimming raw reads, 1.64 × 108, 0.64 × 108, and 1.13 × 108 clean reads were selected from samples of LPS-treated PAH rats, respectively, and 1.16 × 108, 1.11 × 108, and 1.10 × 108 clean reads were selected from control tissue from three paired PAH rats (Supplemental Table 1). Clean reads of each sample were aligned to the human reference genome. The mapped ratio of each sample was greater than 90% (Supplemental Table 2). Deregulated lncRNAs identified by the microarray in PAH rat with a status of acute inflammation. Deregulated mRNAs identified by the microarray in PAH rat with a status of acute inflammation.

DElncRNAs and DEmRNAs in LPS-treated PAH rats

A total 94 up- and 258 down-regulated DElncRNAs were identified in LPS-treated PAH rats. And 445 mRNAs were upregulated and 877 mRNAs were down-regulated when compared with non-inflamed control PAH rats. Respectively, 43 DElncRNAs (36 up-regulation and 7 down-regulation) and 230 DEmRNAs (202 up-regulation and 28 down-regulation) were detected in the lung tissues of LPS-treated PAH rats compared to non-inflamed control rats in accordance with the threshold of P < 0.05 and |log2Fold change| ≥ 2. According to the location and transcriptional orientation, a total of 43 DElncRNAs were divided into five categories: intergenic (27, 62.8%), antisense (8, 18.6%), intronic (3, 7.0%), bidirectional (1, 2.3%), and unclassified (4, 9.3%) (Fig. 1a).
Fig. 1.

Distribution of deregulated long non-coding RNAs (lncRNAs) and heatmaps in pulmonary arterial hypertension (PAH) rats with acute inflammation and in the control group. (a) lncRNAs were divided into five categories: intergenic, antisense, intronic, bidirectional, and unclassified according to their relationships with protein-coding genes. (b) Heatmap showing differentially expressed lncRNAs (DElncRNAs) from lung tissues of PAH rats with acute inflammation compared with lung tissues of PAH control rats. (c) Heatmap showing differentially expressed mRNA (DEmRNA) from lung tissues of PAH rats with acute inflammation compared with lung tissues of PAH control rats. Row and column represent DElncRNAs/DEmRNAs and tissue samples. The color scale indicates log10 fragments per kilobase million of the expression levels of DElncRNAs/DEmRNAs. Red and green indicate up- and down-regulation. N represents PAH rats without inflammation and L represents PAH rats with acute inflammation.

Distribution of deregulated long non-coding RNAs (lncRNAs) and heatmaps in pulmonary arterial hypertension (PAH) rats with acute inflammation and in the control group. (a) lncRNAs were divided into five categories: intergenic, antisense, intronic, bidirectional, and unclassified according to their relationships with protein-coding genes. (b) Heatmap showing differentially expressed lncRNAs (DElncRNAs) from lung tissues of PAH rats with acute inflammation compared with lung tissues of PAH control rats. (c) Heatmap showing differentially expressed mRNA (DEmRNA) from lung tissues of PAH rats with acute inflammation compared with lung tissues of PAH control rats. Row and column represent DElncRNAs/DEmRNAs and tissue samples. The color scale indicates log10 fragments per kilobase million of the expression levels of DElncRNAs/DEmRNAs. Red and green indicate up- and down-regulation. N represents PAH rats without inflammation and L represents PAH rats with acute inflammation. The top 10 DElncRNAs and DEmRNAs (upregulation and down-regulation) are presented in Tables 1 and 2, respectively. Hierarchical clustering of the expression of top 10 DElncRNAs and DEmRNAs (upregulation and down-regulation) show that there was obvious discrimination between LPS-treated PAH and non-inflamed control rats (Fig. 1b and c). The expression of TCONS_00107024 and TCONS_00198427 varied most significantly in DElncRNAs. The expression of Cxcl10 and Lbh varied most significantly in DEmRNAs.
Table 1.

Deregulated lncRNAs identified by the microarray in PAH rat with a status of acute inflammation.

LncRNAsChromosomePositionFC (log2) P
XLOC_0744191418745752–187843613.510.00005
XLOC_139911256162113–561631313.430.0352
XLOC_26689886013206–60765983.260.00005
XLOC_004526169485517–694943732.870.00175
XLOC_0744191418745752–187843612.850.00005
XLOC_03402510106973874–1069760402.840.00005
XLOC_0995551631187149–311942422.830.00005
XLOC_1418042248219427–2482631682.80.00005
XLOC_2683018132665926–1327532922.790.00005
XLOC_108967178811977–88409762.660.0021
XLOC_1406612134217099–134275852−3.170.00005
XLOC_0583331224974340–25021863−2.910.03365
XLOC_0057381156444464–156457900−2.460.0059
XLOC_1384382190946625–191044228−2.190.0003
XLOC_233416624160225–24184120−2.140.00005
XLOC_282901970010577–70037631−2.080.0175
XLOC_174435352875784–52877295−2.010.02115
XLOC_139873253580678–53602678−1.990.00005
ENSRNOG000000555376142404864–142405483−1.990.0001
ENSRNOG00000058261318653319–18654383−1.970.00005
Table 2.

Deregulated mRNAs identified by the microarray in PAH rat with a status of acute inflammation.

mRNA nameSymbolRegulation directionFold change (log2) P
ENSRNOT00000003075Cxcl10Up6.410.00005
ENSRNOT00000003823Cxcl6Up5.900.00005
ENSRNOT00000011509Csf3Up5.890.0151
ENSRNOT00000013732Il6Up5.500.00005
ENSRNOT00000021730Ccl20Up5.420.00005
ENSRNOT00000022827Pla2g2aUp5.400.00005
ENSRNOT00000016541Ptx3Up5.270.00005
ENSRNOT00000003778Cxcl1Up5.200.00005
ENSRNOT00000003759SelpUp5.160.00005
ENSRNOT00000003745Cxcl2Up5.060.00005
ENSRNOT00000071312AABR07027447.1Down−3.560.0002
ENSRNOT00000063989B230307C23RikDown−3.070.0057
ENSRNOT00000091904LbhDown−3.020.00005
ENSRNOT00000061284LbhDown−2.820.0005
ENSRNOT00000014346Wisp2Down−2.720.00005
ENSRNOT00000016984Vamp5Down−2.700.035
ENSRNOT00000068778Rtkn2Down−2.670.00005
ENSRNOT00000071806Cldn5Down−2.640.00005
ENSRNOT00000006203FibinDown−2.600.00005
ENSRNOT00000020528CtgfDown−2.450.00005

qRT-PCR validation of DElncRNAs

To validate the reliability of RNA-seq results, DElncRNAs and DEmRNAs were selected for further qRT-PCR verification. Four DElncRNAs and four mRNAs were chosen for verification. TCONS_00196921 and TCONS_00107023 were upregulated in LPS-treated PAH rats compared with the control rats (P < 0.01). TCONS_00321934 (P < 0.05) and TCONS_00243128 (P < 0.01) were significantly down-regulated in LPS-treated PAH rats compared with control group. Cxcl6 (P < 0.01) and Il-6 (P < 0.01) were upregulated, whereas Lbh (P < 0.001) and Rtkn2 (P < 0.01) were down-regulated (P < 0.05) significantly in the lung tissues of LPS-treated PAH rats (Fig. 2).
Fig. 2.

Quantitative real-time PCR validation of dysregulated differentially expressed (DE) long non-coding RNAs (lncRNAs) and differentially expressed mRNAs (DEmRNAs) in pulmonary arterial hypertension (PAH) rats with acute inflammation compared with matched tissues of control PAH rats. (a) Expression level of lncRNA TCONS_00196921, (b) expression level of lncRNA TCONS_00107023, (c) Expression level of lncRNA TCONS_00321934, (d) expression level of lncRNA TCONS_00243128, (e) Expression level of Cxcl6, (f) expression level of Il-6, (g) Expression level of Lbh and (h) expression level of Rtkn2. N represents PAH rats without inflammation and L represents paired PAH rats with acute inflammation. *P < 0.05, **P < 0.01, ***P < 0.001.

Quantitative real-time PCR validation of dysregulated differentially expressed (DE) long non-coding RNAs (lncRNAs) and differentially expressed mRNAs (DEmRNAs) in pulmonary arterial hypertension (PAH) rats with acute inflammation compared with matched tissues of control PAH rats. (a) Expression level of lncRNA TCONS_00196921, (b) expression level of lncRNA TCONS_00107023, (c) Expression level of lncRNA TCONS_00321934, (d) expression level of lncRNA TCONS_00243128, (e) Expression level of Cxcl6, (f) expression level of Il-6, (g) Expression level of Lbh and (h) expression level of Rtkn2. N represents PAH rats without inflammation and L represents paired PAH rats with acute inflammation. *P < 0.05, **P < 0.01, ***P < 0.001.

GO and KEGG pathway enrichment

We found that 230 mRNAs were differentially expressed. The upregulated mRNAs were enriched in TNF signaling pathway (KEGG: 04668), cytokine–cytokine receptor interaction (KEGG: 04060), NF-ΚB signaling pathway (KEGG: 04064), chemokine signaling pathway (KEGG: 04062), malaria (KEGG: 05144). The down-regulated mRNAs were enriched in Hippo signaling pathway (KEGG: 04390), systemic lupus erythematosus (KEGG: 05322), transcriptional misregulation in cancer (KEGG: 05202), basal cell carcinoma (KEGG: 05217), and cGMP-PKG signaling pathway (KEGG: 04022) (Fig. 3). The important KEGG pathways were found with a P value < 0.05, and they were ranked according to their enrichment scores (−log10 (P-value)). Furthermore, those upregulated mRNAs were significantly enriched in defense response, response to cytokine, immune system process, extracellular space, extracellular region part, cell surface, chemokine receptor binding, chemokine activity, cytokine activity of GO molecular function, cellular component, and biological process, and the downregulated mRNAs were enriched in cardiovascular system development, circulatory system development, multicellular organismal development, protein−DNA complex, actomyosin, nucleosome, protein heterodimerization activity, protein binding, and phosphatidylinositol 3-kinase activity (Fig. 4).
Fig. 3.

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for mRNAs with the 20 highest enrichment scores. (a) KEGG pathway enrichment analysis for upregulated mRNAs. (b) KEGG pathway enrichment analysis for down-regulated mRNAs. The abscissa is -Lg P-value (-LgP). The bigger the -LgP, the smaller the P value, indicating that the enrichment of differentially expressed genes in a given pathway was significant.

Fig. 4.

Gene ontology (GO) enrichment analysis for mRNAs with the 10 highest enrichment scores. (a) GO enrichment analysis for up-regulated mRNAs, (b) GO enrichment analysis for down-regulated mRNAs. Blue bars are biological processes, green are cellular components, and red are molecular functions. The abscissa is -Lg P-value (-LgP). The bigger the -LgP, the smaller the P value, indicating that the enrichment of differentially expressed genes in a given pathway was significant.

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for mRNAs with the 20 highest enrichment scores. (a) KEGG pathway enrichment analysis for upregulated mRNAs. (b) KEGG pathway enrichment analysis for down-regulated mRNAs. The abscissa is -Lg P-value (-LgP). The bigger the -LgP, the smaller the P value, indicating that the enrichment of differentially expressed genes in a given pathway was significant. Gene ontology (GO) enrichment analysis for mRNAs with the 10 highest enrichment scores. (a) GO enrichment analysis for up-regulated mRNAs, (b) GO enrichment analysis for down-regulated mRNAs. Blue bars are biological processes, green are cellular components, and red are molecular functions. The abscissa is -Lg P-value (-LgP). The bigger the -LgP, the smaller the P value, indicating that the enrichment of differentially expressed genes in a given pathway was significant.

Co-expression network among lncRNAs and coding genes

We calculated the PCC on the basis of the expression of DElncRNAs and DEmRNAs to investigate the potential functions of inflammation on PAH. The top 10 upregulated/downregulated DElncRNAs and DEmRNAs were included in the co-expressed network, which contained 10 nodes and 230 edges (Fig. 5). The top five upregulated DEmRNAs were Cxcl10, Cxcl6, Csf3, Il6, and Ccl20, and these mRNAs were mostly associated with inflammation. The down-regulated expressed DEmRNAs were Cldn5, Rtkn2, Vamp5, Wisp2, and Lbh, and so on. These genes are associated with cell structure and function.
Fig. 5.

Co-expression network of 230 and 10 differentially expressed (DE) long non-coding RNAs (DElncRNAs). Circular nodes represent DElncRNAs and rectangle nodes represent DEmRNAs. Green indicates upregulated DEmRNAs and yellow indicates down-regulated DEmRNAs, blue indicates upregulated DElncRNAs, and red indicates down-regulated DElncRNA.

Co-expression network of 230 and 10 differentially expressed (DE) long non-coding RNAs (DElncRNAs). Circular nodes represent DElncRNAs and rectangle nodes represent DEmRNAs. Green indicates upregulated DEmRNAs and yellow indicates down-regulated DEmRNAs, blue indicates upregulated DElncRNAs, and red indicates down-regulated DElncRNA.

Discussion

Inflammation is the basis of many pathophysiological processes. Acute inflammation is the initial reaction of the body to noxious stimulation, whereas chronic inflammation is a process of long-term maladaptive response involving inflammatory activation, tissue damage, and tissue repair. Pulmonary hypertension is related with persistent inflammation and an inflammatory response that leads to pulmonary vascular remodeling and hemodynamic alteration. Enhancement of inflammation, apoptosis, and fibrosis have been identified as three key biomarkers involved in an experimental model of monocrotaline-induced PAH. However, how acute inflammation caused by infection leading to rapidly deteriorating PAH occurs remains unclear. LncRNAs are transcripts without coding protein function. Increasing evidence demonstrates that DElncRNAs are associated with multiple disease pathogenesis processes, such as tumor, heart failure, and inflammation. We investigated the changes and expression profiles of lncRNAs and their potential functional in the lung tissues of LPS-treated PAH rats. In our study, a total 94 up- and 258 down-regulated DElncRNAs were identified in LPS-treated PAH rats. In addition, 445 mRNAs were upregulated and 877 mRNAs were down-regulated in LPS-treated PAH rats. Among these, 36 upregulated lncRNAs and 7 down-regulated lncRNAs, as well as 202 upregulated mRNAs and 28 down-regulated mRNAs had up to 2.0-fold change (P < 0.05). We selected four lncRNAs (TCONS_00196921, TCONS_00107023, TCONS_00321934, and TCONS_00243128) and four mRNAs (Cxcl6, Il-6, Lbh, and Rtkn2) for verification. The results of the qRT-PCR analysis were in accordance with the results of high-throughput sequencing, thus indicating that the RNA-sequencing data were reliable. Thus, our study provided a profound understanding of the role of lncRNAs in LPS-treated PAH rats and throws light on the treatment of PAH patients with acute inflammation. We performed GO term enrichment analysis to identify biological processes, cellular components, and molecular functions associated with the DElncRNAs. We found that the DEmRNAs were greatly enriched in functions related to biological process (cardiovascular system development and defense response), cell components (actomyosin and extracellular space), and molecular functions (protein heterodimerization activity and chemokine receptor binding). KEGG also highlighted the important pathways involved in the inflammation mechanism, such as vascular smooth muscle contraction, Rap1 signaling pathway, TNF signaling pathway, and cytokine–cytokine receptor interaction. Among these pathways, the NF-κB signaling pathway was demonstrated to be the dominant pathway. It is well known that TNF-α increases both acute and chronic heart failure and is connected with the severity and poor outcome of heart failure. In the present study, many DElncRNAs in the lung tissues of LPS-treated PAH rats were found and we predicted their corresponding cis- and trans-targeting mRNAs using bioinformatic analysis. LncRNA TCONS_00198427 was predicted to act on IL-6. In PAH patients and PAH animal models, levels of the inflammatory cytokine IL-6 are elevated.[16,17] It has been proven that IL-6 is increased in acute heart failure patients and is associated with severity and unfavorable outcomes of heart failure.[18,19] In addition, a previous study reported that MALAT1 can raise the expression of TNF-α and IL-6 in endothelial cells. However, the role of IL-6 and its relationship to lncRNAs has not been extensively studied. lncRNA TCONS_00107024 could interact with matrix metallopeptidase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1. MMP-9 was upregulated in PAH rats with acute inflammation and it has been involved in the process of sepsis, atherosclerosis, and chronic obstructive pulmonary disease. MMP-9 is strictly regulated by its specific inhibitor of metalloproteinase 1. A recent study showed that the lncRNA XIST interacting with MiR-124 could affect the expression of MMP-9. MMP-9 could cause the remodeling of the left ventricular and is involved in acute processes.[26,27] A former clinical study also showed that brain natriuretic peptide decreased collagen synthesis and increased MMP activity. The co-expression network among lncRNAs and coding genes showed abundant information; for instance, one study revealed that knockdown Rtkn2 in vitro led to apoptosis and the inhibition of invasion. Vamp5 was involved in docking and membrane fusion during membrane transport events. In other words, these findings are consistent with our results and give us some clues for advanced studies to explore the connection between lncRNAs and cardiovascular disease. Furthermore, these reports suggest that these DElncRNAs may play important roles in LPS-treated PAH rats. Our study has some limitations. We used software to predict the function of lncRNAs and the relationship between lncRNAs and mRNAs, and the construction of network and pathway analyses was based on bioinformatics analysis; thus, its validity should be tested further by carrying out designed experiments. In conclusion, our study demonstrated that 352 lncRNAs and 1322 mRNAs were expressed differently in lung tissues of LPS-treated PAH rats. lncRNAs may be involved in pivotal biological pathway regulation. The expression profile of lncRNAs and mRNAs changed in the lungs of PAH rats in circumstances of acute inflammation, which may provide new insights into the study of PAH. Click here for additional data file. Supplemental material, PUL879393 Supplemetal Material for Long non-coding RNA expression profiling in the lungs of pulmonary arterial hypertension rats with acute inflammation by Yue Yang, Yanan Cao, Gang Qin, Lu Wang, Qian Li, Sisi Dai, Lizhe Guo, Qulian Guo, Yong Gang Peng, Bin Duan and E. Wang in Pulmonary Circulation
  30 in total

1.  Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression.

Authors:  Hsiangling Teo; Sourav Ghosh; Hendrik Luesch; Arkasubhra Ghosh; Ee Tsin Wong; Najib Malik; Anthony Orth; Paul de Jesus; Anthony S Perry; Jeffrey D Oliver; Nhan L Tran; Lisa J Speiser; Marc Wong; Enrique Saez; Peter Schultz; Sumit K Chanda; Inder M Verma; Vinay Tergaonkar
Journal:  Nat Cell Biol       Date:  2010-07-11       Impact factor: 28.824

2.  Exosomes Derived from Human Pulmonary Artery Endothelial Cells Shift the Balance between Proliferation and Apoptosis of Smooth Muscle Cells.

Authors:  Lin Zhao; Hui Luo; Xiaohui Li; Tangzhiming Li; Jingni He; Qiangqiang Qi; Yuwei Liu; Zaixin Yu
Journal:  Cardiology       Date:  2017-01-10       Impact factor: 1.869

Review 3.  The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer.

Authors:  Daniela Terracciano; Sara Terreri; Filomena de Nigris; Valerio Costa; George A Calin; Amelia Cimmino
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-09-13       Impact factor: 10.680

4.  Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts.

Authors:  Jae-Hyung Lee; Chen Gao; Guangdun Peng; Christopher Greer; Shuxun Ren; Yibin Wang; Xinshu Xiao
Journal:  Circ Res       Date:  2011-10-27       Impact factor: 17.367

5.  Silencing of RTKN2 by siRNA suppresses proliferation, and induces G1 arrest and apoptosis in human bladder cancer cells.

Authors:  Yi-Xiang Liao; Jin-Min Zeng; Jia-Jie Zhou; Guang-Hua Yang; Kun Ding; Xian-Jue Zhang
Journal:  Mol Med Rep       Date:  2016-04-14       Impact factor: 2.952

6.  Plasma cytokine parameters and mortality in patients with chronic heart failure.

Authors:  M Rauchhaus; W Doehner; D P Francis; C Davos; M Kemp; C Liebenthal; J Niebauer; J Hooper; H D Volk; A J Coats; S D Anker
Journal:  Circulation       Date:  2000-12-19       Impact factor: 29.690

7.  Effects of Sevoflurane on Hemodynamics and Inducible Nitric Oxide Synthase/Soluble Guanylate Cyclase Signaling Pathway in a Rat Model of Pulmonary Arterial Hypertension.

Authors:  Gang Qin; Hui Luo; Xiaoqing Yin; Lu Wang; Junjie Zhang; Yanan Cao; Zhong Zhang; Zhi Ye; E Wang
Journal:  Anesth Analg       Date:  2017-07       Impact factor: 5.108

8.  Sildenafil improves long-term effect of endothelial progenitor cell-based treatment for monocrotaline-induced rat pulmonary arterial hypertension.

Authors:  Chia-Hung Yen; Tzu-Hsien Tsai; Steve Leu; Yung-Lung Chen; Li-Teh Chang; Han-Tan Chai; Sheng-Ying Chung; Sarah Chua; Ching-Yen Tsai; Hsueh-Wen Chang; Sheung-Fat Ko; Cheuk-Kwan Sun; Hon-Kan Yip
Journal:  Cytotherapy       Date:  2012-12-11       Impact factor: 5.414

9.  MMP-9/TIMP-1 imbalance induced in human dendritic cells by Porphyromonas gingivalis.

Authors:  Ravi Jotwani; Sridhar V K Eswaran; Surinder Moonga; Christopher W Cutler
Journal:  FEMS Immunol Med Microbiol       Date:  2010-04

10.  A long noncoding RNA protects the heart from pathological hypertrophy.

Authors:  Wei Li; Chiou-Hong Lin; Pei Han; Jin Yang; Ching Shang; Sylvia T Nuernberg; Kevin Kai Jin; Weihong Xu; Chieh-Yu Lin; Chien-Jung Lin; Yiqin Xiong; Huanchieh Chien; Bin Zhou; Euan Ashley; Daniel Bernstein; Peng-Sheng Chen; Huei-Sheng Vincent Chen; Thomas Quertermous; Ching-Pin Chang
Journal:  Nature       Date:  2014-08-10       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.